Sierra Oncology Inc (SRRA)       54.99  +0.02 (+0.04%)

54.99  +0.02 (+0.04%)

US82640U4040 - Common Stock - After market: 54.99 0 (0%)

Sierra Oncology Inc54.99

NASDAQ:SRRA (6/30/2022, 7:00:01 PM)+0.02 (+0.04%)

After market: 54.99 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 05-06 2022-05-06/bmo Earnings (Next) 08-03 2022-08-03
Ins Owners N/A Inst Owners 82.99%
Market Cap 1.34B Shares 24.42M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 76
IPO 07-16 2015-07-16

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

SRRA Daily chart

Company Profile

Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of cancer. The company is headquartered in Vancouver, British Columbia and currently employs 109 full-time employees. The company went IPO on 2015-07-16. The Company’s lead product candidate, momelotinib, which is a selective and orally bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor under investigation for the treatment of myelofibrosis. The firm is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), which is a key regulator of cell cycle progression and the DDR network. SRA141 is a bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).

Company Info

Sierra Oncology Inc

2150 ? 885 West Georgia Street, Suite 110

Vancouver BRITISH COLUMBIA V6C 3E8

P: 16045586536.0

CEO: Stephen G. Dilly

Employees: 109

Website: https://www.sierraoncology.com/

News

News Image18 days ago - Sierra OncologySierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug AdministrationNews Imagea month ago - InvestorPlace6 Biotech Stocks to Buy Now Ahead of These June Catalysts

These biotech stocks face some key make-or-break events in June that could have big implication for their futures.

News Imagea month ago - InvestorPlace3 Biotech Stocks to Buy Before They Boom

It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.

News Imagea month ago - Sierra OncologyMomelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual MeetingNews Image2 months ago - Sierra OncologySierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting

SRRA Twits

Here you can normally see the latest stock twits on SRRA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example